Bruce Ruggeri

9.6k total citations · 3 hit papers
121 papers, 6.8k citations indexed

About

Bruce Ruggeri is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Bruce Ruggeri has authored 121 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 60 papers in Molecular Biology and 16 papers in Cancer Research. Recurrent topics in Bruce Ruggeri's work include Pancreatic and Hepatic Oncology Research (15 papers), Cancer-related Molecular Pathways (12 papers) and Angiogenesis and VEGF in Cancer (12 papers). Bruce Ruggeri is often cited by papers focused on Pancreatic and Hepatic Oncology Research (15 papers), Cancer-related Molecular Pathways (12 papers) and Angiogenesis and VEGF in Cancer (12 papers). Bruce Ruggeri collaborates with scholars based in United States, Italy and Japan. Bruce Ruggeri's co-authors include Paul McGonigle, Andres J. Klein–Szanto, Sheila Miknyoczki, Joseph R. Testa, Lingyi Huang, Craig A. Dionne, Jin Q. Cheng, Deborah Lang, Deborah A. Altomare and Dennis K. Watson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Blood.

In The Last Decade

Bruce Ruggeri

120 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.

1996 634 citations Bruce Ruggeri et al. profile →
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

2008 597 citations Mangeng Cheng, Bruce Ruggeri et al. profile →
Animal models of human disease: Challenges in enabling translation

2013 390 citations Bruce Ruggeri et al. profile →

Peers

Countries citing papers authored by Bruce Ruggeri

Since Specialization

Citations

This map shows the geographic impact of Bruce Ruggeri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Ruggeri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Ruggeri more than expected).

Fields of papers citing papers by Bruce Ruggeri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce Ruggeri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Ruggeri. The network helps show where Bruce Ruggeri may publish in the future.

Co-authorship network of co-authors of Bruce Ruggeri

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce Ruggeri. A scholar is included among the top collaborators of Bruce Ruggeri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce Ruggeri. Bruce Ruggeri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies 2023 ·Cancer Research Communications ·(unknown), Michael Hulse, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Neha Bhagwat, Joseph Rager, Bruce Ruggeri, Peggy Scherle, (unknown)	15
2	Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer 2019 ·European Urology Oncology ·Ramiro Vázquez, Gianluca Civenni, (unknown), Dheeraj Shinde, (unknown), Martina Marchetti‐Deschmann, (unknown), Bruce Ruggeri, Phillip C.C. Liu, Giuseppina M. Carbone, Carlo V. Catapano	12
3	The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer 2018 ·Gynecologic Oncology ·Andrew J. Wilson, Matthew C. Stubbs, Phillip Liu, Bruce Ruggeri, Dineo Khabele	88
4	The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1 2013 ·Oncogenesis ·Claudia Voena, Filomena Di Giacomo, Elena Panizza, Lucia D’Amico, Francesco Boccalatte, Elisa Pellegrino, (unknown), (unknown), Fabrizio Tabbò, Chiara Ambrogio, Cinzia Martinengo, Laurent Bonello, (unknown), Jörg Hamm, Roberto Chiarle, Mangeng Cheng, Bruce Ruggeri, Enzo Médico, Giorgio Inghirami	26
5	CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers 2011 ·Molecular Cancer Therapeutics ·Mangeng Cheng, Matthew R. Quail, Diane E. Gingrich, Gregory R. Ott, Lihui Lü, Weihua Wan, Mark S. Albom, Thelma S. Angeles, Lisa D. Aimone, (unknown), Rodolfo Machiorlatti, (unknown), Mark A. Ator, Bruce D. Dorsey, Giorgio Inghirami, Bruce Ruggeri	59
6	Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE 2011 ·International Immunopharmacology ·Matthew M. Seavey, Lily Lu, (unknown), (unknown), Bruce Ruggeri	53
7	Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models 2010 ·Bioorganic & Medicinal Chemistry Letters ·Eugen F. Mesaros, Jason P. Burke, Jonathan D. Parrish, (unknown), Andrew V. Anzalone, Thelma S. Angeles, Mark S. Albom, Lisa D. Aimone, Matthew R. Quail, Weihua Wan, Lihui Lü, Zeqi Huang, Mark A. Ator, Bruce Ruggeri, Mangeng Cheng, Gregory R. Ott, Bruce D. Dorsey	27
8	TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs 2008 ·Bioorganic & Medicinal Chemistry Letters ·Ted L. Underiner, Bruce Ruggeri, Lisa D. Aimone, Mark S. Albom, Thelma S. Angeles, Hong Chang, Robert L. Hudkins, Kathryn Hunter, Kurt A. Josef, Candy Robinson, (unknown), Shi Yang, Allison L. Zulli	8
9	Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases 2008 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Allison L. Zulli, Edward R. Bacon, Ted L. Underiner, Candy Robinson, Hong Chang, Sheila Miknyoczki, Jennifer V. Grobelny, Bruce Ruggeri, Shi Yang, Mark S. Albom, Thelma S. Angeles, Lisa D. Aimone, Robert L. Hudkins	15
10	CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models 2007 ·Molecular Cancer Therapeutics ·Bruce Ruggeri, Ted L. Underiner, Diane E. Gingrich, Robert L. Hudkins, Thelma S. Angeles, Mark S. Albom, Hong Chang, Candy Robinson, Kathryn Hunter, Paweł Dobrzański, Susan Jones‐Bolin, Lisa D. Aimone, Mark A. Ator, Jean‐Marc Herbert, Françoise Bono, Paul Schaefer, Pierre Casellas, (unknown), John P. Mallamo, Jeffry L. Vaught	2
11	PAX6 is expressed in pancreatic adenocarcinoma and is downregulated during induction of terminal differentiation 2007 ·Molecular Carcinogenesis ·Deborah Lang, Joseph B. Mascarenhas, Sara Powell, (unknown), (unknown), Bruce Ruggeri	20
12	Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes 2006 ·Journal of Clinical Investigation ·Roberto Piva, Elisa Pellegrino, Michela Mattioli, Luca Agnelli, Luigia Lombardi, Francesco Boccalatte, Giulia Costa, Bruce Ruggeri, Mangeng Cheng, Roberto Chiarle, Giorgio Palestro, Antonino Neri, Giorgio Inghirami	133
13	Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis 2006 ·Bioorganic & Medicinal Chemistry Letters ·Rabindranath Tripathy, (unknown), (unknown), Mohamed Iqbal, J. B. Singh, Edward R. Bacon, Thelma S. Angeles, Shi Yang, Mark S. Albom, Candy Robinson, Hong Chang, Bruce Ruggeri, John P. Mallamo	88
14	Trk inhibitors provide better efficacy than a VEGF-R kinase inhibitor in combination with gemcitabine on improving survival in an orthotopic model of human PDAC 2005 ·Cancer Research ·Susan Jones‐Bolin, Kathryn Hunter, Hugh Zhao, Andres J. Klein–Szanto, Bruce Ruggeri	1
15	Vascular endothelial growth factor mediates vasogenic edema in acute lead encephalopathy 2004 ·Annals of Neurology ·Mir Ahamed Hossain, (unknown), Sheila Miknyoczki, Bruce Ruggeri, Bachchu Lal, John Laterra	28
16	CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. 2003 ·PubMed ·Christopher J. Strock, Jong‐In Park, Mark Rosen, Craig A. Dionne, Bruce Ruggeri, Susan Jones‐Bolin, Samuel R. Denmeade, Douglas W. Ball, Barry D. Nelkin	83
17	Retinal Vascular Leakage in Early Diabetes is Normalized In Vivo by the Oral VEGF Receptor Kinase Inhibitor, CEP-7055 2002 ·Investigative Ophthalmology & Visual Science ·(unknown), AC Clermont, (unknown), Susan Jones‐Bolin, Bruce Ruggeri, (unknown)	1
18	Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: Expression patterns and effects onIn vitro invasive behavior 1999 ·International Journal of Cancer ·Sheila Miknyoczki, Deborah Lang, Lingyi Huang, Andres J. Klein–Szanto, Craig A. Dionne, Bruce Ruggeri	153
19	Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. 1997 ·Journal of Clinical Investigation ·David S. Weinberg, Bruce Ruggeri, Michael T. Barber, S B Biswas, (unknown), Scott A. Waldman	86
20	Steady-state mRNA expression for growth factors in DMBA-induced rat mammary tumors 1990 ·Cancer Letters ·Bruce Ruggeri, David M. Klurfeld, David Kritchevsky, Kevin K. Frick	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact